Related references
Note: Only part of the references are listed.Anticancer or carcinogenic? The role of estrogen receptor beta in breast cancer progression
Kang Shen et al.
PHARMACOLOGY & THERAPEUTICS (2023)
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Nicolas Guedeney et al.
DRUG DISCOVERY TODAY (2023)
PROTAC targeted protein degraders: the past is prologue
Miklos Bekes et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer
Xiangping Deng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases
Xin Luo et al.
ISCIENCE (2022)
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
Yating Wang et al.
CANCER AND METASTASIS REVIEWS (2022)
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Jaeki Min et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors
Anh S. Lu et al.
MOLECULAR PHARMACEUTICS (2021)
A New Era in ER plus Breast Cancer: Best-in-Class Oral Selective Estrogen Receptor Degrader (SERD) Designed as an Endocrine Backbone Treatment
Pengcheng Shao
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Peter S. Dragovich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
Thomas L. Gonzalez et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer
Ming He et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer
Yunlong Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)
Yuanyuan Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Estrogen signaling: An emanating therapeutic target for breast cancer treatment
Tanmay Saha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity
Zhiye Hu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism
Jun Wu et al.
CANCER LETTERS (2019)
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Jiantao Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives
Shagufta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer
Wentao Nin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy
Kaiwei Liang et al.
CELL (2018)
Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor alpha
Yanhong Jiang et al.
ACS CHEMICAL BIOLOGY (2018)
Full antagonism of the estrogen receptor without a prototypical ligand side chain
Sathish Srinivasan et al.
NATURE CHEMICAL BIOLOGY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Estrocen Receptor β as a Pharmaceutical Target
Margaret Warner et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
Yuechao Zhao et al.
CANCER RESEARCH (2017)
Endocrine treatment in breast cancer: Cure, resistance and beyond
Konstantinos Tryfonidis et al.
CANCER TREATMENT REVIEWS (2016)
TT-seq maps the human transient transcriptome
Bjorn Schwalb et al.
SCIENCE (2016)
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
Chu Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Mitotic Transcriptional Activation: Clearance of Actively Engaged Pol II via Transcriptional Elongation Control in Mitosis
Kaiwei Liang et al.
MOLECULAR CELL (2015)
Estrogen receptor mutations and functional consequences for breast cancer
Christoforos Thomas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein Protein Interaction between the von Hippel- Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
Carles Galdeano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Ilaria Paterni et al.
STEROIDS (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides
Manghong Zhu et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2012)
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Yukihiro Itoh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Menno P. Creyghton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
A. Rodriguez-Gonzalez et al.
ONCOGENE (2008)
Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: Estrogen antagonists of unusual structure
HB Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Development of protacs to target cancer-promoting proteins for ubiquitination and degradation
KM Sakamoto et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Structural insights into the mode of action of a pure antiestrogen
ACW Pike et al.
STRUCTURE (2001)
Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer
BS Katzenellenbogen et al.
BREAST CANCER RESEARCH (2000)
Share Paper
